RDY vs the Top Picks average
| Pillar | RDY | Book avg | Diff |
|---|---|---|---|
| Quality | 67 | 83 | -16 |
| Growth | 49 | 89 | -40 |
| Value | 16 | 76 | -60 |
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
One point per daily run; read From → To for the actual range.
RDY at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
| 30-day change | -2.3% |
|---|---|
| 90-day change | -3.3% |
| Forward EPS estimate | $0.64 |
Over the last 90 days, what analysts expect RDY to earn is drifting lower (-3.3%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Dr. Reddy's Laboratories Limited (RDY): score, valuation & FAQ
Dr. Reddy's Laboratories Limited (RDY) is a Drug Manufacturers - Specialty & Generic company that scores 33.8 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (B+), while FCF (C-) rate weaker. On valuation, RDY sits about 602% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 58% next year, slowing to 4% a year by year ten.
Is RDY a good stock to buy?
Bull Rankings scores RDY 33.8 out of 100 on its quality-growth model, which is a weak reading. That is driven by D/E (B+). A score is a quantitative screen of Dr. Reddy's Laboratories Limited's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does RDY score 33.8 on Bull Rankings?
The score leans on quality at 67.2 out of 100, with value the weakest pillar at 16.1 — the three combine geometrically, so a weak one cannot be papered over by a strong one. RDY earns its highest marks on D/E (B+), and is held back by FCF (C-). Each signal is graded against sector-aware thresholds rather than one absolute bar, so RDY is measured against Drug Manufacturers - Specialty & Generic peers, not against the market as a whole.
Is RDY overvalued or undervalued?
Based on $12.48, RDY sits about 602% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 58% next year, slowing to 4% a year by year ten. It trades at a 28.4x P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in RDY?
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
New to these metrics? See the guides and the methodology.